InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, launches a new data annotation service designed to support researchers and analysts who require specific, literature-based biological data for use in QSP modeling, analysis, or decision-making.
The new service allows clients to submit targeted data requests related to diseases, tissues, cell types, and cytokines. InSysBio team will populate its CYTOCON or fIVE databases with newly curated data, ensuring availability in the most convenient and standardized format for subsequent analysis and integration.
Key features of the deliverables (all integrated into CYTOCON DB and fIVE DB):
1. Annotated Data Tables:
2. Summary Statistics Table
3. Visualizations
Each data request follows a one-month workflow. The first week is dedicated to a feasibility assessment, during which the team evaluates the availability and volume of the requested data in scientific literature. If the data cannot be identified, clients receive detailed feedback, and the query may be refined. Depending on the scope and complexity of the request, the team can process up to 20 scientific articles per month, resulting in approximately 800 annotated concentration values for CYTOCON DB and 130 annotated parameters for fIVE DB. All annotations are performed by a dedicated team consisting of one professional annotator and one reviewer, ensuring a high standard of quality and consistency throughout the process.
For further details or to data request, please feel free to contact us: support@insysbio.com
To learn more about CYTOCON DB, please visit https://cytocon.insysbio.com/Index.aspx
To learn more about fIVE DB, please visit https://5db.insysbio.com/Index.aspx
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2018 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
| |||
|
5
|
6
1.
06 Nov 2018 17:27
Investigation of amyloid pathology mechanisms and prediction of clinical trial results using QSP model
InSysBio presents the video of Tatiana Karelina’s talk in framework of session “From translational PKPD models to quantitative system pharmacology in neurodegeneration drug development” at the 9th American Conference on Pharmacometrics (ACoP9):
|
7
|
8
|
9
|
10
|
11
|
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
|
19
|
20
|
21
|
22
|
23
|
24
|
25
|
|
26
1.
26 Nov 2018 14:03
InSysBio updates Immune Response Template online
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, today announced a release of updated version of Immune Response Template (IRT) online. The main update in new 2.1.0 version is myeloid-derived suppressor cells (MDSCs). Published human in vitro and in vivo data were analyzed to reconstruct monocytic MDSCs (Mo-MDSCs) and granulocytic MDSCs (Gr-MDSCs) life cycles, derive equations and identify parameters.
|
27
|
28
|
29
|
30
| ||